Literature DB >> 20503259

Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Arno Hänninen1, Merja Soilu-Hänninen, Christiane S Hampe, Angie Deptula, Kelly Geubtner, Jorma Ilonen, Mikael Knip, Helena Reijonen.   

Abstract

BACKGROUND: Glutamic acid decarboxylase (GAD) is a rate-limiting enzyme in the synthesis of gamma-amino butyric acid (GABA) and an important autoantigen both in patients with type 1 diabetes (T1D) and stiff-person syndrome (SPS). Autoantibodies (GADA) to the 65-kDa isoform of GAD are a characteristic feature in both diseases. Approximately 30% of patients with SPS develop diabetes, yet, it is unclear to which extent co-existing autoimmunity to GAD65 and other islet autoantigens determines the risk of developing T1D.
METHODS: In this study, we monitored CD4+ T-cell responses to GAD65 and proinsulin in a patient with SPS who remained normoglycaemic during the 46-month follow-up.
RESULTS: Fluctuating but persistent T-cell reactivity to GAD65 was identified, as well as T-cell reactivity to proinsulin at one time point. The majority of the T-cell clones isolated from the patient with SPS produced high levels of Th2 cytokines (IL-13, IL-5 and IL-4). We also examined levels of GADA, insulin and IA-2 autoantibodies, and epitope specificity of GADA. In both serum and cerebrospinal fluid (CSF), GADA levels were high, and GADA persisted throughout the follow-up. Despite T-cell reactivity to both GAD65 and proinsulin, autoantibodies to other islet autoantigens did not develop.
CONCLUSIONS: Further follow-up will determine whether the beta-cell autoimmunity observed in this patient will eventually lead to T1D.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503259      PMCID: PMC2878280          DOI: 10.1002/dmrr.1083

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  54 in total

1.  A novel monoclonal antibody specific for the N-terminal end of GAD65.

Authors:  C S Hampe; P Lundgren; T L Daniels; L P Hammerle; S M Marcovina; A Lernmark
Journal:  J Neuroimmunol       Date:  2001-02-01       Impact factor: 3.478

2.  Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes.

Authors:  C S Hampe; L P Hammerle; L Bekris; E Ortqvist; I Kockum; O Rolandsson; M Landin-Olsson; C Törn; B Persson; A Lernmark
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

3.  GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop.

Authors:  Gustavo Fenalti; Ruby H P Law; Ashley M Buckle; Christopher Langendorf; Kellie Tuck; Carlos J Rosado; Noel G Faux; Khalid Mahmood; Christiane S Hampe; J Paul Banga; Matthew Wilce; Jason Schmidberger; Jamie Rossjohn; Ossama El-Kabbani; Robert N Pike; A Ian Smith; Ian R Mackay; Merrill J Rowley; James C Whisstock
Journal:  Nat Struct Mol Biol       Date:  2007-03-25       Impact factor: 15.369

4.  Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.

Authors:  W Richter; Y Shi; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

5.  Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes.

Authors:  N Ujihara; K Daw; R Gianani; E Boel; L Yu; A C Powers
Journal:  Diabetes       Date:  1994-08       Impact factor: 9.461

6.  Autoantibodies associated with Type I diabetes mellitus persist after diagnosis in children.

Authors:  K Savola; E Sabbah; P Kulmala; P Vähäsalo; J Ilonen; M Knip
Journal:  Diabetologia       Date:  1998-11       Impact factor: 10.122

7.  Detection of CD4+ autoreactive T cells in T1D using HLA class II tetramers.

Authors:  Helena Reijonen; William W Kwok; Gerald T Nepom
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 8.  Autoimmune mechanisms in type 1 diabetes.

Authors:  Mikael Knip; Heli Siljander
Journal:  Autoimmun Rev       Date:  2008-04-30       Impact factor: 9.754

9.  Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes.

Authors:  K Daw; A C Powers
Journal:  Diabetes       Date:  1995-02       Impact factor: 9.461

10.  T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity.

Authors:  M Costa; A Saiz; R Casamitjana; M Fernández Castañer; A Sanmartí; F Graus; D Jaraquemada
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

View more
  10 in total

Review 1.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

2.  Immunoendocrinology: When (neuro)endocrinology and immunology meet.

Authors:  Christian A Koch; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

3.  Stiff Person Syndrome and Type 1 Diabetes Mellitus: a Case of the Chicken or the Egg?

Authors:  John Tyler Rathbun; Jacob Imber
Journal:  J Gen Intern Med       Date:  2019-02-19       Impact factor: 5.128

4.  Production of primary human CD4⁺ T cell lines and clones.

Authors:  Jessica Matthis; Helena Reijonen
Journal:  Methods Mol Biol       Date:  2013

5.  Increased islet antigen-specific regulatory and effector CD4+ T cells in healthy individuals with the type 1 diabetes-protective haplotype.

Authors:  Xiaomin Wen; Junbao Yang; Eddie James; I-Ting Chow; Helena Reijonen; William W Kwok
Journal:  Sci Immunol       Date:  2020-02-14

6.  Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.

Authors:  M Chéramy; C S Hampe; J Ludvigsson; R Casas
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

Review 7.  Mechanistic basis of immunotherapies for type 1 diabetes mellitus.

Authors:  Wenhao Chen; Aini Xie; Lawrence Chan
Journal:  Transl Res       Date:  2013-01-22       Impact factor: 7.012

Review 8.  Anti-glutamic acid decarboxylase antibody positive neurological syndromes.

Authors:  Hassaan Tohid
Journal:  Neurosciences (Riyadh)       Date:  2016-07       Impact factor: 0.906

Review 9.  Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.

Authors:  Deepti Pilli; Alicia Zou; Fiona Tea; Russell C Dale; Fabienne Brilot
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

Review 10.  Human Leukocyte Antigen (HLA) and Islet Autoantibodies Are Tools to Characterize Type 1 Diabetes in Arab Countries: Emphasis on Kuwait.

Authors:  Mohamed Jahromi; Ebaa Al-Ozairi
Journal:  Dis Markers       Date:  2019-11-20       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.